While I support IP for individuals, I don’t support it for large companies and definitely not for drug companies.

I understand the money involved in making drugs, but you should not be able to monopolize a life saving drug and charge exorbitant money for it. Most of the initial drug research is done by scientists not associated with drug company.

  • TA202301
    link
    fedilink
    11 year ago

    They are a lot more affordable because the generic drug manufacturers didn’t pay for the research and development. They’re taking the product of someone else’s hard work, voting it, and selling it for less. That’s easy when you didn’t spend money developing the drug. There had to be some profit in making drugs if you want companies to do it but what I’m saying is that that should not be unlimited.

    • @[email protected]OP
      link
      fedilink
      11 year ago

      I disagree. If the patent was never filed the compound is hard to reverse engineer. Even then it has to go to drug trials.

      As I stated before most of the research is done by researchers. And drug companies mostly spend on advertising and lobbying and executive pay compared to the money spent on research.

      • TA202301
        link
        fedilink
        11 year ago

        Like I said…if the research GND development is publicly funded then the drug should be public and we should pay enough for it to pay for the research into the next drug. Socialism.

        If a company pays for the research and development then they should be allowed to make their investment back with reasonable but not unlimited profit and not forever. Limited capitalism.

        • @thepianistfroggollum
          link
          01 year ago

          No, don’t you see? Companies should spend billions of dollars developing a drug and just give it away at cost.

          • TA202301
            link
            fedilink
            -11 year ago

            Straw man. Come back when you’re not going to use childish devices and are ready to have a real discussion.